特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の鎌状赤血球症治療市場:2019~2023年

Global Sickle Cell Disease Treatment Market 2019-2023

発行 TechNavio (Infiniti Research Ltd.) 商品コード 778284
出版日 ページ情報 英文 113 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.17円で換算しております。
世界の鎌状赤血球症治療市場:2019~2023年 Global Sickle Cell Disease Treatment Market 2019-2023
出版日: 2019年01月16日 ページ情報: 英文 113 Pages
概要

世界の鎌状赤血球症治療市場は2023年までにCAGR11%で拡大すると予測されています。CDCによると、2017年、米国での鎌状赤血球症患者はおよそ10万人にのぼります。

当レポートでは、世界の鎌状赤血球症治療市場について調査し、市場の動向とセグメント別動向、地域別予測、市場に参入する企業のプロファイルについてまとめています。

第1章 エグゼクティブサマリー

第2章 レポートの範囲

第3章 市況

  • 市場エコシステム
  • 市場特性
  • 市場セグメンテーション分析

第4章 市場規模

  • 市場の定義
  • 2018年の市場規模
  • 市場規模と予測:2018~2023年

第5章 ファイブフォース分析

第6章 適応別市場セグメンテーション

  • 市場セグメンテーション
  • 比較
  • 貧血
  • βサラセミア
  • その他
  • 市場の機会

第7章 消費者動向

第8章 地域別動向

  • 地域別セグメンテーション
  • 比較
  • 南北アメリカ
  • 欧州・中東・アフリカ
  • アジア太平洋地域
  • 主要国
  • 市場の機会

第9章 意思決定の枠組み

第10章 市場促進因子と阻害因子

第11章 市場動向

第12章 ベンダー環境

第13章 ベンダー分析

  • 網羅されるベンダー
  • ベンダー分類
  • 市場ポジショニング
  • ADDMEDICA
  • Bristol-Myers Squibb
  • Emmaus Medical
  • Novartis
  • Pfizer

第14章 付録

図表
  • Exhibit 01: Global pharmaceuticals market
  • Exhibit 02: Segments of global pharmaceuticals market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Five forces analysis 2018
  • Exhibit 10: Five forces analysis 2023
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2018
  • Exhibit 17: Indication - Market share 2018-2023 (%)
  • Exhibit 18: Comparison by indication
  • Exhibit 19: Sickle cell anemia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 20: Sickle cell anemia - Year-over-year growth 2019-2023 (%)
  • Exhibit 21: Sickle beta thalassemia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: Sickle beta thalassemia - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Others - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: Others - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Market opportunity by indication
  • Exhibit 26: Customer landscape
  • Exhibit 27: Market share by geography 2018-2023 (%)
  • Exhibit 28: Geographic comparison
  • Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 34: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 36: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 37: Key leading countries
  • Exhibit 38: Market opportunity
  • Exhibit 39: Impact of drivers and challenges
  • Exhibit 40: Gene therapy pipeline for sickle cell
  • Exhibit 41: Vendor landscape
  • Exhibit 42: Landscape disruption
  • Exhibit 43: Vendors covered
  • Exhibit 44: Vendor classification
  • Exhibit 45: Market positioning of vendors
  • Exhibit 46: ADDMEDICA - Vendor overview
  • Exhibit 47: ADDMEDICA - Business segments
  • Exhibit 48: ADDMEDICA - Organizational developments
  • Exhibit 49: ADDMEDICA - Key offerings
  • Exhibit 50: ADDMEDICA - Key customers
  • Exhibit 51: Bristol-Myers Squibb - Vendor overview
  • Exhibit 52: Bristol-Myers Squibb - Business segments
  • Exhibit 53: Bristol-Myers Squibb - Organizational developments
  • Exhibit 54: Bristol-Myers Squibb - Geographic focus
  • Exhibit 55: Bristol-Myers Squibb - Key offerings
  • Exhibit 56: Bristol-Myers Squibb - Key customers
  • Exhibit 57: Emmaus Medical - Vendor overview
  • Exhibit 58: Emmaus Medical - Business segments
  • Exhibit 59: Emmaus Medical - Organizational developments
  • Exhibit 60: Emmaus Medical - Geographic focus
  • Exhibit 61: Emmaus Medical - Key offerings
  • Exhibit 62: Emmaus Medical - Key customers
  • Exhibit 63: Novartis - Vendor overview
  • Exhibit 64: Novartis - Business segments
  • Exhibit 65: Novartis - Organizational developments
  • Exhibit 66: Novartis - Geographic focus
  • Exhibit 67: Novartis - Segment focus
  • Exhibit 68: Novartis - Key offerings
  • Exhibit 69: Novartis - Key customers
  • Exhibit 70: Pfizer - Vendor overview
  • Exhibit 71: Pfizer - Business segments
  • Exhibit 72: Pfizer - Organizational developments
  • Exhibit 73: Pfizer - Geographic focus
  • Exhibit 74: Pfizer - Segment focus
  • Exhibit 75: Pfizer - Key offerings
  • Exhibit 76: Pfizer - Key customers
目次
Product Code: IRTNTR30672

About this market:

Strong pipeline of drugs to drive market growth. The pipeline for sickle cell disease comprises strong pharmaceutical companies with novel therapies in the late stages of clinical trials and various mid and small pharmaceutical companies with early-stage pipeline drugs. The strong efficacy of these drugs in the early stages of clinical trials has led to a positive opinion from the regulatory bodies. Thus, helping the vendors with quick development of these drugs. Technavio's analysts have predicted that the sickle cell disease treatment market will register a CAGR of over 11% by 2023.

Market Overview:

High prevalence of sickle cell disease

The global sickle cell disease treatment market has witnessed a significant increase in the number of cases of sickle cell diseases in recent years. For instance, according to the CDC. in 2017, sickle cell diseases affected approximately 100,000 Americans. While it is rather rare in Hispanic-Americans and Asian-Americans, the disease is more common in African-Americans, with the prevalence being as high as one per every 365 people.

Lack of approved therapies

Despite blood transfusion being heavily used to treat sickle cell diseases, the market faces a major challenge from the lack of approved therapies. Currently, the market has only three approved therapies for sickle cell diseases, and six molecules are in Phase Ill of clinical trials.

For the detailed list of factors that will drive and challenge the growth of the sickle cell disease treatment market during the 2019-2023, view our report.

Competitive Landscape:

The market appears to be fragmented and with the presence of several companies including Novartis and Pfizer the competitive environment is quite intense. Factors such as the high prevalence of sickle cell disease and the strong pipeline of drugs, will provide considerable growth opportunities to sickle cell disease treatment manufactures. ADDMEDICA, Bristol-Myers Squibb, Emmaus Medical, Novartis, and Pfizer are some of the major companies covered in this report.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1. Preface
  • 2.2. Preface
  • 2.3. Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY INDICATION

  • Market segmentation by indication
  • Comparison by indication
  • Sickle cell anemia - Market size and forecast 2018-2023
  • Sickle beta thalassemia - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by indication

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • ADDMEDICA
  • Bristol-Myers Squibb
  • Emmaus Medical
  • Novartis
  • Pfizer

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations

PART 15: EXPLORE TECHNAVIO